MA
MRKR icon

MCF Advisors’s Marker Therapeutics MRKR Stock Holding History

MCF Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-609
Closed -$2.77K – 967
2023
Q3 		$2.77K Hold
609
– – ﹤0.01% 733
2023
Q2 		$1.89K Buy
+609
New +$1.06K ﹤0.01% 721

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MCF Advisors's MRKR Position: Q4 2023 in Review

MCF Advisors sold out of Marker Therapeutics (MRKR) in Q4 2023, closing a stake of 609 shares — an estimated $2.77K sold.

MCF Advisors first reported a position in MRKR in Q2 2023 and held it in 2 quarters. The position peaked at $2.77K in Q3 2023. 26 funds tracked by Wall St. Rank hold MRKR as of Q4 2023.

  • MCF Advisors reported no remaining Marker Therapeutics position as of Q4 2023 after selling out during the quarter.
  • MCF Advisors sold 609 Marker Therapeutics shares in Q4 2023, an estimated $2.77K.
  • MCF Advisors first reported a position in Marker Therapeutics in Q2 2023 and held it in 2 quarters.
  • MCF Advisors's Marker Therapeutics position peaked at $2.77K in Q3 2023.
  • 26 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2023.

Based on MCF Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.